Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

NCT00947167 is registered in ClinicalTrials.gov with Pamela L. Kunz as lead sponsor.

NCT NCT00947167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00947167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Lead sponsor
Pamela L. Kunz
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2009
Completion date
May 31, 2010
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adrenal gland tumors, carcinoid tumors, multiple endocrine neoplasia, neuroblastoma, neuroendocrine tumors, pancreatic neuroendocrine tumors